Chinese Hepatolgy ›› 2025, Vol. 30 ›› Issue (4): 458-461.

• Liver Tumor • Previous Articles     Next Articles

The application of TACE, targeted immunotherapy combined with 125I particle implantation in patients with unresectable giant hepatocellular carcinoma

SHEN Xiang-jing, SU Hai-chuan   

  1. Department of Oncology, Second Affiliated Hospital of Air Force Medical University, Xi' an 710038, China
  • Received:2024-10-20 Online:2025-04-30 Published:2025-06-17
  • Contact: SU Hai-chuan,Email:13730192059@163.com

Abstract: Objective To evaluate the efficacy of transcatheter arterial chemoembolization (TACE), targeted immunotherapy combined with 125I particle implantation in patients with unresectable giant hepatocellular carcinoma (HCC). Methods A retrospective analysis was conducted on 88 patients with unresectable giant HCC who were treated at Second Affiliated Hospital of Air Force Medical University from December 2020 to January 2024. The patients were divided into two groups based on the treatment modality: a TACE combined with targeted immunotherapy group (control group, 43 cases), and a TACE+targeted immunotherapy+125I particle implantation group (observation group, 45 cases), with all patients receiving four treatment cycles. Both groups showed no vascular invasion or extrahepatic metastasis at baseline, and there were no significant differences in baseline data (P>0.05), and ensuring comparability. The clinical efficacy, immune function, tumor marker levels (AFP, PIVKA-Ⅱ), progression-free survival (PFS), and adverse reactions between these two groups were compared after four cycles of treatment. Results The efficacy of treatment in the observation group was significantly higher than that in the control group (86.67% vs. 62.79%) (P<0.05). After treatment, the levels of AFP and PIVKA-Ⅱ in the observation group were (63.05±7.51) ng/mL and (113.25±11.01) mAU/mL, respectively, while in the control group, they were (80.84 ± 9.42) ng/mL and (150.64±16.13) mAU/mL (P<0.05). Three months post-treatment, the maximum lesion cross-sectional area had decreased in both groups. The average overall survival (OS) in the observation and control groups was 21.43 (20.34, 22.59) months and 18.41 (16.98, 19.76) months, respectively (P<0.05). Conclusion TACE combined with targeted immunotherapy and 125I particle implantation can improve immune function and enhance treatment efficacy in patients with unresectable giant HCC.

Key words: Unresectable massive liver cancer, Transcatheter arterial chemoembolization, 125I particle implantation, Targeted immunity, Curative effect